Pfizer: The Market Is Wrong (NYSE:PFE)

Alexandros Michailidis Investment thesis My previous bullish thesis about Pfizer Inc. (NYSE:PFE) from October 2023 did not age well, as the stock delivered a -10% total return over the last half-year, substantially lagging behind the broader market. Despite it, today I want to reiterate my bullish thesis because recent developments suggest that the business continues…

Read More

Pfizer Inc. (PFE) TD Cowen 44th Annual Health Care Conference

Pfizer Inc. (NYSE:PFE) TD Cowen 44th Annual Health Care Conference March 4, 2024 11:10 AM ET Company Participants David Denton – Chief Financial Officer and Executive Vice President Conference Call Participants Steve Scala – TD Cowen Steve Scala Well, good morning once again. We’re delighted to have Pfizer here at Cowen’s 44th Annual Healthcare Conference….

Read More

Pfizer Stock: The 6.3% Yield Is A appealing (NYSE:PFE)

Michael M. Santiago Pfizer (NYSE:PFE) submitted a better than expected earnings card for the fourth fiscal quarter last week. Despite a drop-off in COVID-19 related product revenues, Pfizer has been able to deliver solid organic top line growth in the fourth quarter as well as FY 2023. The pharmaceutical giant also confirmed its financial outlook…

Read More

Pfizer Is Part Of The 2024 Healthcare Sector Rally Cohort (NYSE:PFE)

JHVEPhoto Pfizer Inc. (NYSE:PFE) stock has continued to reel from the exhaustion of COVID dollars. Specifically, the 2023 downturn has been primarily dragged by a faster-than-expected normalization of Comirnaty vaccine and Paxlovid COVID treatment uptakes. In addition to the $5.6 billion write-off on Paxlovid/Comirnaty inventory in Q3, management has also provided a weaker-than-expected guidance for…

Read More

Pfizer: The Bears Have Won This Round (NYSE:PFE)

DamianKuzdak We previously covered Pfizer (NYSE:NYSE:PFE) in September 2023, discussing its pessimistic performance as the decelerating COVID-19 portfolio and underperforming bolt-on acquisitions had contributed to its lowered FY2023 guidance range. Combined with the overly aggressive R&D efforts, expensive acquisitions, and deteriorating balance sheet, we had preferred to cautiously rate the stock as a Hold then….

Read More